Effect of enterokinetic prucalopride on intestinal motility in fast rats

Hui-Bin Qi, Jin-Yan Luo, Xin Liu

Hui-Bin Qi, Jin-Yan Luo, Xin Liu, Department of Gastroenterology, Second Hospital of Xi’an Jiaotong University, Xi’an 710004, Shaanxi Province, China

Correspondence to: Dr. Hui-Bin Qi, Department of Gastroenterology, Second Hospital of Xi’an Jiaotong University, Xi’an 710004, Shaanxi Province, China. qihuibin123@hotmail.com

Received: 2003-01-04 Accepted: 2003-02-18

Abstract

AIM: To evaluate the effects of prucalopride on intestinal prokinetic activity in fast rats and to provide experimental basis for clinical treatment of gastrointestinal motility diseases.

METHODS: Gastrointestinal propulsion rate was measured by the migration rate of activated charcoal, which reflexes gastrointestinal motility function. 120 Spraque-Dawley rats were randomly divided into four groups and received an intravenous injection of physiological saline (served as control), prucalopride 1 mg/kg, prucalopride 2 mg/kg and cisapride 1 mg/kg, respectively. The gastrointestinal propulsion rate was measured 1, 2 or 4 hours after intravenous injection of the drugs.

RESULTS: Significant accelerations of gastrointestinal propulsion rate in prucalopride 1 mg/kg and 2 mg/kg groups were found compared with control group at 2 and 4 hours (83.2%±5.5%, 81.7%±8.5% vs 70.5%±9.2%, P<0.01; 91.2%±2.2%, 91.3%±3.9% vs 86.8%±2.6%, P<0.01). The gastrointestinal propulsion rates at 1, 2 or 4 hours were faster in prucalopride 1 mg/kg and 2 mg/kg groups than in cisapride group (84.0%±11.7%, 77.1%±11.9% vs 66.3%±13.6%, P<0.01; 83.2%±5.5%, 81.7%±8.5% vs 75.4%±5.9%, P<0.01; 91.2%±2.2%, 91.3%±3.9% vs 88.6%±3.5%, P<0.05). No difference of gastrointestinal propulsion rate was found between prucalopride 1 mg/kg group and prucalopride 2 mg/kg group (P>0.05).

CONCLUSION: Prucalopride accelerates intestinal motility in fast rats, and has no dose dependent effect.

Qi HB, Luo JY, Liu X. Effect of enterokinetic prucalopride on intestinal motility in fast rats. World J Gastroenterol 2003; 9 (9): 2065-2067

http://www.wjgnet.com/1007-9327/9/2065.asp

INTRODUCTION

Prucalopride is the first representative of the novel class of benzofurans, and is a highly specific and selective 5-HT4 receptor agonist. Prucalopride can exert effect on intestinal prokinetic activity in fast rats.

MATERIALS AND METHODS

Experimental animals

One hundred and twenty healthy male Sprague-Dawley (SD) rats weighing 200-250 g were purchased from the Experimental Animal Center of Xi’an Jiaotong University. The rats were housed in rat cages at 22-25 °C with free access to standard rat pellet food and water for 10 days. They were fasted for 48 hours with free access to water.

Chemicals

Prucalopride and cisapride were kindly provided by Janssen Research Foundation. Prucalopride was dissolved in sterile, 0.57 mol/L ascorbic acid. Activated charcoal was purchased from the Chemical Factory of the Forestry Science Institute of China. Arabic gum powder was purchased from the Third Chemical Factory of Tianjin. Diethyl ether was purchased from Xi’an Chemical Factory.

Experimental procedure

The rats were randomly divided into four groups. Each group had 30 rats. The first group served as control and received intravenous injection of physiological saline under ether anaesthesia. The second group and the third received intravenous injection of prucalopride 1 mg/kg and 2 mg/kg under ether anaesthesia, and the fourth group received intravenous injection of cisapride 1 mg/kg in the same way. They then received intragastric injection of 100 g/L activated charcoal suspension (10 mg/kg, 100 g/L activated charcoal and 100 g/L Arabic gum powder respectively) through a specially designed orogastric cannula introduced through the mouth. The animals were killed 1, 2 and 4 hours respectively after ether anesthesia by cervical dislocation and decapitation. They had a laparotomy and migration of activated charcoal from esophagus-stomach junction to the most distal point of migration, and were expressed as distance (cm) migration by the stain. At 1 hour after injection, the most distal point of migration was in the small intestine and gastrointestinal (GI) propulsion rate was expressed as: gastrointestinal propulsion rate = the migration distance of activated charcoal(cm) / the distance from esophagus-stomach junction to ileocecal opening(cm)×100 %. At 2 hours after injection, the most distal point of migration was all in the distal small intestine or proximal colon and at 4 hour after injection, the most distal point of migration was in the colon. So gastrointestinal propulsion rate was expressed as: gastrointestinal propulsion rate = the migration distance of activated charcoal(cm) / the distance from esophagus-stomach junction to large intestine terminal(cm)×100 %.

Statistical analysis

Data were expressed as ±x. Statistical analyses used were unpaired t test. Statistical significance was taken as P<0.05.

RESULTS

One hour effect of prucalopride

At 1 hour after injection, the most distal point of migration was in the small intestine. Compared with control group, in prucalopride 1 mg/kg group and prucalopride 2 mg/kg group, GI propulsion rate had no difference (P>0.05). Prucalopride at a
dose of either 1 or 2 mg/kg had no significant effect on gastrointestinal motility. Compared with cisapride group, GI propulsion rate had differences in prucalopride 1 mg/kg group and prucalopride 2 mg/kg group ($P<0.01$, Table 1).

**Table 1** One hour effect of prucalopride on intestinal motility in SD rats ($n=10$)

| Group                  | GI length (cm) | Migration of activated charcoal (cm) | GI propulsion rate (%) |
|------------------------|----------------|--------------------------------------|------------------------|
| Control                | 82.9±12.2      | 63.8±10.5                            | 77.9±7.5               |
| Prucalopride (1 mg/kg) | 70.9±4.1       | 59.7±9.5                             | 84.0±1.1*              |
| Prucalopride (2 mg/kg) | 73.8±11.7      | 57.0±12.8                            | 77.1±11.9*             |
| Cisapride (1 mg/kg)    | 78.1±10.7      | 52.2±14.4                            | 66.3±13.6              |

* $P<0.05$, $P<0.01$, vs cisapride.

**Two hour effect of prucalopride**

At 2 hours after injection, the most distal point of migration was in the distal small intestine or proximal colon. Compared with control group, GI propulsion rate had significant differences in prucalopride 1 mg/kg group and prucalopride 2 mg/kg group ($P<0.01$).

Prucalopride at a dose of either 1 or 2 mg/kg significantly increased GI propulsion, suggesting that prucalopride might enhance gastrointestinal motility. Compared with cisapride group, GI propulsion rate had differences in prucalopride 1 mg/kg group and prucalopride 2 mg/kg group ($P<0.01$, $P<0.05$, Table 2).

**Table 2** Two hour effect of prucalopride on intestinal motility in SD rats ($n=10$)

| Group                  | GI length (cm) | Migration of activated charcoal (cm) | GI propulsion rate (%) |
|------------------------|----------------|--------------------------------------|------------------------|
| Control                | 91.9±11.8      | 63.9±3.8                             | 70.5±9.2               |
| Prucalopride (1 mg/kg) | 87.1±8.5       | 72.6±10.0                            | 83.2±5.9*              |
| Prucalopride (2 mg/kg) | 100.1±12.2     | 81.9±14.0                            | 81.7±8.5*              |
| Cisapride (1 mg/kg)    | 94.5±12.3      | 72.0±6.9                             | 75.4±5.9               |

* $P<0.05$, $P<0.01$, vs cisapride; $P<0.01$, vs control.

**Four hour effect of prucalopride**

At 4 hours after injection, the most distal point of migration was in the colon. Compared with control group, GI propulsion rate had significant differences in prucalopride 1 mg/kg group and prucalopride 2 mg/kg group ($P<0.01$). Prucalopride at a dose of either 1 or 2 mg/kg significantly increased GI propulsion, suggesting that prucalopride might enhance gastrointestinal motility. Compared with cisapride group, GI propulsion rate had differences in prucalopride 1 mg/kg group and prucalopride 2 mg/kg group ($P<0.05$, Table 3).

**Table 3** Four hour effect of prucalopride on intestinal motility in SD rats ($n=10$)

| Group                  | GI length (cm) | Migration of activated charcoal (cm) | GI propulsion rate (%) |
|------------------------|----------------|--------------------------------------|------------------------|
| Control                | 89.9±8.6       | 78.0±7.3                             | 86.8±2.6               |
| Prucalopride (1 mg/kg) | 83.7±5.1       | 76.3±5.2                             | 91.2±2.2*              |
| Prucalopride (2 mg/kg) | 97.4±9.8       | 87.3±10.4                            | 91.3±3.9*              |
| Cisapride (1 mg/kg)    | 99.5±12.7      | 88.1±13.7                            | 88.6±3.5               |

* $P<0.05$, vs cisapride; $P<0.01$, vs control.

**Response to different doses of prucalopride**

At 1, 2 and 4 hours after prucalopride injection, GI propulsion rate in prucalopride 1 mg/kg group was not different from that in prucalopride 2 mg/kg group ($P>0.05$, Table 1, 2 and 3). The effect of prucalopride was not clearly dose related.

**DISCUSSION**

Prucalopride (R093877) is a newly synthesized enterokinetic agent which is a benzofuran derivative with the chemical structure of 4-anoimo-5-chloro-2, 3-dihydro-N-[1(3-methoxypropyl)-4-piperidinyl]-7-benzofuranarboxamide monochloride. It is a highly specific and selective 5-HT$_4$ receptor agonist$^{[1]}$. *In vitro* animal experiments have shown facilitation of cholinergic$^{[2]}$ and excitatory non-adrenergic,non-cholinergic (NANC) neurotransmission. It is the first compound known to enhance NANC transmission in colonic prepatations of guinea pig. Since cholinergic neurons and NANC neurons are known to play an important part in physiological regulation of colonic motility, it is likely that constipation will be favourably influenced by compounds facilitating NANC excitatory neurotransmission. Prucalopride is a specific and selective for 5-HT$_4$ receptor and is devoid of affinity to M$_3$ cholinoceptors, 5HT$_3A$ and 5HT$_3$ receptors, and cholinesterases. *In vivo* canine colonic studies confirmed the selectivity of the effects on 5-HT, receptors, as the selective and potent 5-HT$_3$ antagonist completely prevented the effects of prucalopride. But some 5-HT$_3$, agonist prokinetics stimulate 5HT$_3A$ and 5HT$_3$ receptors. *In vivo* and *in vitro* studies have shown that prucalopride can facilitate gastric, small intestinal, and colonic motility$^{[3,5]}$.

This study in fast rats showed that prucalopride had no significant effects on GI propulsion rate at 1 hour after intravenous injection. However, it significantly increased GI propulsion rate at 2, 4 hour after intravenous injection, suggesting that prucalopride might enhance gastrointestinal motility in the distal small intestine and colon instead of the stomach and proximal small intestine. This is consistent with the observations of Emmanuel et al in healthy volunteers. Emmanuel showed that 1 mg and 2 mg of prucalopride shortened orocaecal transit and whole gut transit, and suggested that prucalopride accelerated upper gut and colonic transit. Orocacical transit was measured by lactulose-hydrogen breath test. Whole gut transit was measured by radio-opaque markers. Bouras et al$^{[6]}$ reported that gastrointestinal and colonic transits were measured by scintigraphic techniques in healthy humans, and a daily dose of 0.5, 1, 2, or 4 mg prucalopride accelerated colonic transit, partly by stimulating proximal colonic emptying, but did not alter gastric or small bowel transit. Poen et al$^{[7]}$ reported that prucalopride was well tolerated by healthy subjects and had a markedly consistent effect on stool frequency and colonic transit. Prucalopride, given orally or intravenously, altered colonic motility in the fast conscious dog in a dose-dependent manner. It induced significant migrating contractions, stimulated proximal colon and inhibited contractile motility patterns of distal colon by stimulating 5-HT$_4$ receptors$^{[4,8]}$. It deserves further study in patients with constipation. The fact that prucalopride did not affect stomach and proximal small intestine in fast rats does not preclude its potential beneficial effects in pathological states such as delayed gastric emptying. For example, in an animal model for delayed gastric emptying, prucalopride accelerated gastric emptying. In humans, Emmanuel et al observed that prucalopride shortened orocaecal transit, while Bouras et al found that prucalopride did not alter gastric or small bowel transit. This discrepancy probably was resulted from differences in methods used to measure transit. In Emmanuel et al studies, lactulose-hydrogen breath test of a liquid marker
could measure orocecal transit, but could not differentiate effects on stomach or small intestine. Whole gut transit was measured by radio-opaque markers. In Bouras et al studies, a scintigraphic technique was used to measure gastrointestinal and colonic transit. The effects of prucalopride on stomach or small intestine deserves further study. Patients with idiopathic constipation had postprandial sigmoid motor activity. Prolonged colonic motility was recorded in patients with slow transit constipation. Slow transit constipation was common. Laxatives are often ineffective in treating constipation. An alternative therapeutic approach is to target serotonin-4 receptors, which are involved in initiating peristalsis. Some Chinese herbal medicines can promote gastrointestinal motility and be used to treat constipation.

The reason for the lack of a dose-response effect of prucalopride on gastrointestinal motility is unclear. Maybe the dose groups were too few and the extent of doses was too narrow. It should design more dose groups to deserve the dose related effects. The dose dependent effects on significant colonic migrating have been more clearly shown by intravenous injection than by oral administration of prucalopride in dogs. Briejer et al observed a sigmoid dose-response curve in a dose of 0.001 to 1.25 mg/kg, the linear part of the curve was between 0.02 and 0.31 mg/kg. But Bouras et al reported that in healthy humans, a daily dose of 0.5, 1, 2, or 4 mg prucalopride was almost equally effective, and lack of dose-response effects. The lack of stronger effects of 2 mg over 1 mg in this study might be resulted from turning off the signal: mechanisms that attenuate signaling by G protein-coupled receptors, by which serotonin receptors are characterized. In futher study, we should investigate the dose related effects of prucalopride in patients with constipation and slow colonic transit.

This study showed that prucalopride whether 1 mg/kg or 2 mg/kg doses accelerated gastrointestinal propulsion rate compared with cisapride 1 mg/kg dose.

In conclusion, prucalopride can accelerate intestinal motility compared with cisapride 1 mg/kg dose.

REFERENCES

1 Prins NH, Akkermans LM, Lefebvre RA, Schuurkes JA. Characterization of the receptors involved in the 5-HT-induced excitation of canine antral longitudinal muscle. Br J Pharmacol 2001; 134: 1351-1360

2 Leclere PG, Lefebvre RA. Presynaptic modulation of cholinergic neurotransmission in the human proximal stomach. Br J Pharmacol 2002; 135: 135-142

3 Prins NH, van Der Grijn A, Lefebvre RA, Akkermans LM, Schuurkes JA. S-HT(4) receptors mediating enhancement of contractility in canine stomach; an in vitro and in vivo study. Br J Pharmacol 2001; 132: 1943-1947

4 Briejer MR, Prins NH, Schuurkes JA. Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs. Naurogastroenterol Motil 2001; 13: 465-472

5 Jin JG, Foxx-Orenstein AE, Grider JR. Propulsion in guinea pig colon induced by 5-hydroxytryptamine (HT) via 5-HT4 and 5-HT3 receptors. J Pharmacol Exp Ther 1999; 288: 93-97

6 Bouras EP, Camilleri M, Burton DD, McKinzie S. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut 1999; 44: 662-666

7 Poen AC, Felt-Bersma RJ, Van Dongen PA, Mewissen SG. Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Aliment Pharmacol Ther 1999; 13: 1493-1497

8 Briejer MR, Schuurkes JA, Sarna SK. Idiopathic constipation: too few stools and too little knowledge. Trends Pharmacol Sci 1999; 20: 1-3

9 Li FJ, Zhou YY, Zhang XC, Shen SR. A postprandial manometric recording of sigmoid motor activity in patients with idiopathic colonic constipation. Shiji Huaren Xiaohua Zazhi 2002; 10: 1232-1233

10 Rao SS, Sadeghi P, Batterson K, Beatty J. Altered periodic rectal motor activity: a mechanism for slow transit constipation. Nutr Gastroenterol Motil 2001; 13: 593-598

11 Zhang WW, Li Y. Psychiatric and psychologic factors of functional gastrointestinal disorders. Shiji Huaren Xiaohua Zazhi 2002; 10: 1324-1328

12 Tian B, Yang SL, Li YH, Duan QH, Chen GT, Li F, Ma SF. Pathologic changes and clinical significance of colonic myenteric plexus in patients with slow transit constipation. Shiji Huaren Xiaohua Zazhi 2000; 8: 1385-1388

13 Yu DH. Suggestions on surgical treatment of constipation. Shiji Huaren Xiaohua Zazhi 1999; 7: 169-170

14 Gao F, Zhang SB, Zhang LY, Cai WQ, Tong WD, Li FZ, Li WH. Ultrastructural abnormalities of colonic myenteric plexus in patients with slow transit constipation. Shiji Huaren Xiaohua Zazhi 1999; 7: 1049-1051

15 Tomita R, Tanjoh K, Fujisaki S, Ikeda T, Fukuzawa M. Regulation of the enteric nervous system in the colon of patients with slow transit constipation. H epatogastroenterology 2002; 49: 1540-1544

16 Wald A. Slow Transit Constipation. Curr Treat Options Gastroenterol 2002; 5: 279-283

17 Emmanuel AV, Roy AJ, Nicolls TJ, Kamm MA. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther 2002; 16: 1347-1356

18 Alaradi O, Barkin JS. Irritable bowel syndrome: update on pathogenesis and management. M et Princ Pract 2002; 11: 2-17

19 Krogh K, Jensen MB, Gandrup P, Laurberg S, Nilsson J, Kerstens R, DePauw M. Efficacy and tolerability of prucalopride in patients with constipation due to spinal cord injury. Scand J Gastroenterol 2002; 37: 431-436

20 Sloots CE, Poen AC, Kerstens R, Stevens M, DePauw M, Van Oene JC, Mewissen SG, Felt-Bersma RJ. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther 2002; 16: 759-767

21 De Schryver AM, Andriessen GI, Samos M, Smout AJ, Goossen HG, Akkermans LM. The effects of the specific SHT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteers. Aliment Pharmacol Ther 2002; 16: 603-612

22 Kamm MA. Review article: the complexity of drug development for irritable bowel syndrome. Aliment Pharmacol Ther 2002; 16: 343-351

23 Boeckxstaens GE, Bartelsman JF, Lauwers L, Tylgat GN. Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride. Am J Gastroenterol 2002; 97: 194-197

24 Ahn J, Ehrenpreis ED. Emerging treatments for irritable bowel syndrome. Expert Opin Pharmacother 2002; 3: 9-21

25 Talley NJ. Serotoninergic neuroenteric modulators. Lancet 2001; 358: 2061-2068

26 Talley NJ. Drug therapy options for patients with irritable bowel syndrome. Am J Gastroenterol Care 2001; 7(8 Suppl): S256-S267

27 De Ponti F, Tonini M. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs 2001; 61: 317-332

28 De Schryver AM, Samson M. New developments in the treatment of irritable bowel syndrome. Scand J Gastroenterol Suppl 2000; 238: 32-42

29 Bouras EP, Camilleri M, Burton DD, Thomforde G, McKinzie S, Zinsmeister AR. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001; 120: 354-360

30 Scarpignato C, Pelosi I. Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility. Can J Gastroenterol 1999; 13(Suppl A): 50A-65A

31 Zhu JZ. New development of the gastrointestinal prokinetic agents. Xin Xiaohua Bingu Xzazhi 2001; 9: 1439-1444

32 Zhu JZ, Yang GH, Leng ER, Chen DF. Gastrointestinal motility promoting action of traditional Chinese medicine. Shiji Huaren Xiaohua Zazhi 1999; 7: 689-690

Edited by Yuan HT and Wang XL